查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1300977

美國大麻素市場規模、份額和趨勢分析報告：按產品類型、按應用、細分趨勢：2023-2030

U.S. Cannabinoids Market Size, Share & Trends Analysis Report By Product Type (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabigerol (CBG)), By Application (Inflammation, Pain Management), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 86 Pages | 商品交期: 2-10個工作天內

價格

美國大麻素市場增長和趨勢

美國大麻素市場規模預計到 2030 年將達到 603.6 億美元，2023 年至 2030 年復合年增長率為 15.3%。

越來越多的消費者選擇分離的大麻素產品，在增加臨床研究以了解和擴大與大麻素相關的應用的幫助下，推動了美國整體市場的增長。

大麻素日益增加的健康益處在許多研究和臨床試驗中都顯示出積極的結果，導致 CBD 等大麻素在多種疾病中的使用範圍擴大。 此外，醫療保健專業人員針對某些健康狀況越來越多地開出大麻素（尤其是 CBD）處方，這有助於進一步增加對這些產品的需求。 例如，2020 年對美國皮膚科醫生的一項調查發現，7,176 名受訪者中約 91% 對向患者開基於 CBD 的產品持積極態度。 然而，不推薦大麻用於醫療用途的主要原因是缺乏與大麻素相關的知識和限制。

此外，許多研究表明，使用大麻對減少化療引起的噁心和嘔吐具有積極作用。 癌症治療的另一個副作用是化療引起的周圍神經病變（CIPN）。 多項臨床試驗和研發正在進行中，以開發基於大麻的藥物來治療 CIPN。 例如，2022年6月，梅奧診所與國家癌症研究所共同發起了一項評估外用CBD在CIPN症狀管理中的功效的研究，該研究預計將於2024年4月完成。

此外，領先的公司正在合作開發與大麻素相關的新穎應用程序，以滿足不斷增長的需求，使公司能夠獲得有助於改善其供應鍊和產品開發的資源。我可以。 此外，許多公司還注重產品發布，以擴大產品組合。 例如，2023年2月，SAVO Cannabis 獲得了 Brightsmith Capital Partners 的資金，用於開發新的大麻種植基因設施。

美國大麻素市場報告亮點

  • 2022 年，大麻二酚 (CBD) 細分市場佔據最大份額，達到 26.7%。 這是因為 CBD 不僅用於藥物治療，還用於運動恢復、健康、美容和皮膚護理等活動。
  • 由於慢性疼痛的患病率不斷增加以及大麻素相關的鎮痛特性，預計疼痛管理領域將以最快的複合年增長率增長。
  • 由於神經系統疾病患病率上升以及與使用大麻素治療神經系統疾病相關的研究不斷增加，神經系統疾病細分市場到 2022 年將佔據 22.1% 的巨大市場份額。
  • 隨著消費者尋求含有這些化合物的新型創新產品，次要大麻素的供應量不斷增加預計將推動整個市場的增長。
  • 主導市場的主要公司有 Mile High Labs、Global Cannabinoids、GenCanna、High Purity Natural Products、Rhizo Sciences、CBD Inc.、LaurelCrest、Fresh Bros Hemp Company、Precision Plant Molecules、BulKanna、Zero Point Extraction, LLC 等。

內容

第一章調查方法及範圍

  • 市場細分和範圍
  • 調查方法
  • 信息獲取
  • 信息或數據分析
  • 市場形成和驗證
  • 型號詳細信息
  • 調查假設
  • 輔助信息列表
  • 縮寫列表
  • 目的

第 2 章執行摘要

  • 市場前景
  • 分部展望
  • 競爭考慮因素

第 3 章美國大麻素市場變量、趨勢和範圍

  • 市場體系展望
    • 家長市場
  • 監管場景
  • 市場動態
    • 市場驅動因素分析
    • 市場製約因素分析
  • 美國大麻素市場分析工具
    • 美國大麻素市場 - PESTLE 分析
    • 美國大麻素市場 - 波特的分析
  • 新型冠狀病毒的影響分析
  • 供應鏈分析
    • 供應鏈分析 - CBD 消費保健品
  • 產品採用模式分析
    • 大麻二酚 (CBD)
    • 四氫大麻酚 (THC)
    • 大麻酚 (CBN)
    • 大麻二酚酸 (CBDA)
    • 其他
  • 生物合成大麻素
  • 美國次要大麻素市場的未來趨勢
    • 產品多元化：
    • 提高微量大麻素的可用性：
    • 更多品牌進入市場：
    • 對自然療法的需求不斷增長：
  • TAM-SAM-SOM 分析
  • 行業 KOL 成績單
  • 主要受訪者的主要分析

第 4 章美國大麻素市場細分分析：按產品類型劃分，2018-2030 年

  • 定義和範圍
  • 2022 年和 2030 年產品類型市場份額分析
  • 細分儀表板
  • 2018-2030 年美國大麻素市場（按產品類型）
  • 2018-2030 年市場規模、預測和趨勢分析
    • 大麻二酚 (CBD)
    • 四氫大麻酚 (THC)
    • 大麻酚 (CBN)
    • 大麻二酚酸 (CBGA)
    • 大麻酚 (CBG)
    • 大麻環烯 (CBC)
    • 四氫大麻二酚 (THCV)
    • 其他

第五章美國大麻素市場細分分析：按應用劃分，2018-2030

  • 定義和範圍
  • 2022 年和 2030 年應用市場份額分析
  • 細分儀表板
  • 2018-2030 年美國大麻素市場（按應用）
  • 2018-2030 年市場規模、預測和趨勢分析
    • 炎症
    • 疼痛管理
    • 神經系統疾病
    • 癌症
    • 其他

第 6 章。美國大麻素市場 - 競爭分析

  • 主要市場進入者的最新趨勢和影響分析
  • 公司分類
  • 企業市場分析
  • 公司簡介
    • Mile High Labs
    • Global Cannabinoids
    • GenCanna
    • CBD Inc.
    • Precision Plant Molecules
    • Rhizo Sciences
    • LaurelCrest
    • Fresh Bros Hemp Company
    • BulKanna
    • High-Purity Natural Products
    • Zero Point Extraction, LLC
Product Code: GVR-4-68039-255-9

U.S. Cannabinoids Market Growth & Trends

The U.S. cannabinoids market size is expected to reach USD 60.36 billion by 2030, registering a CAGR of 15.3% from 2023 to 2030, according to a new report by Grand View Research, Inc. The increasing number of consumers opting for isolated cannabinoid products aided by growing clinical studies to understand and expand applications associated with cannabinoids is driving the growth of the overall market in the U.S. Moreover, the growing new entrants in the market further leading to the expansion of the availability of products is propelling this growth.

The growing benefits associated with cannabinoids on health have been showing affirmative results in a number of research and clinical trials, which has led to expansion in the use of cannabinoids, such as CBD, for various conditions, which in turn has increased the demand for cannabinoid products in the country. In addition, the rising prescription of cannabinoids by medical practitioners, mainly CBD, for certain health conditions has further helped in increasing the demand for these products. For instance, according to a survey of dermatologists carried out in the U.S., in 2020, out of 7176 respondents, around 91% were affirmative about prescribing CBD-based products to their patients. However, the major reason for the non-recommendation of cannabis for medical use was due to the lack of or limited knowledge associated with cannabinoids.

Moreover, many studies suggest affirmative results of cannabis use in reducing the instances of nausea and vomiting caused by chemotherapy. Some other adverse effects of cancer treatment are Chemotherapy-induced Peripheral Neuropathy (CIPN). Multiple clinical trials and research studies are ongoing to develop cannabis-based medication for treating CIPN. For instance, in June 2022, a study to assess the efficacy of topical CBD in managing symptoms of CIPN was sponsored by Mayo Clinic in collaboration with National Cancer Institute, and this study is expected to be completed by April 2024.

Furthermore, major companies are collaborating for the development of novel applications linked with cannabinoids to meet the rising demand which enables businesses to use their resources to help with improvements in supply chain and product development. Moreover, a number of players are also focusing on product launches to expand their product portfolio. For instance, in February 2023, SAVO Cannabis received funding from Brightsmith Capital Partners for the development of new cannabis cultivation genetic facility focusing on the development of cannabis for specific effects majorly targeting body and mind for life-enhancing purposes.

U.S. Cannabinoids Market Report Highlights

  • In 2022, Cannabidiol (CBD) segment held the largest share of 26.7% owing to the adoption of CBD not only in medication but also in activities such as sports recovery, wellness, beauty, and skincare
  • Pain management segment is anticipated to grow at the fastest CAGR due to the increasing prevalence of chronic pain and analgesic properties associated with cannabinoids
  • Neurological disorders segment accounted for a significant market share of 22.1% in 2022 due to the growing research associated with the use of cannabinoids in neurological conditions with the increasing prevalence of the conditions
  • The increasing availability of minor cannabinoids is expected to drive the growth of the overall market as consumers seek out new and innovative products containing these compounds
  • Key players dominating the market include Mile High Labs; Global Cannabinoids; GenCanna; High Purity Natural Products; Rhizo Sciences; CBD Inc.; LaurelCrest; Fresh Bros Hemp Company; Precision Plant Molecules; BulKanna; Zero Point Extraction, LLC

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation and Scope
    • 1.1.1 Segment scope
    • 1.1.2 Regional scope
    • 1.1.3 Estimates and forecast timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database:
    • 1.3.2 GVR's internal database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary research
    • 1.3.5 Details of primary research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach: Commodity Flow Approach
  • 1.7 Research Assumptions
  • 1.8 List of Secondary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective 1
    • 1.10.2 Objective 2
    • 1.10.3 Objective 3
    • 1.10.4 Objective 4

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Competitive Insights

Chapter 3 U.S. Cannabinoids Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent market
  • 3.2 Regulatory Scenario
  • 3.3 Market Dynamics
    • 3.3.1 Market drivers analysis
      • 3.3.1.1 Growing number of new entrants in the market leading to expansion in product availability
      • 3.3.1.2 Increasing number of consumers opting for isolated cannabinoid products
      • 3.3.1.3 Growing number of clinical studies on the use of cannabinoids for specific applications
      • 3.3.1.4 Rising awareness about cannabinoid products and their use in health and wellness
    • 3.3.2 Market restraint analysis
      • 3.3.2.1 High price of cannabinoids-based products
      • 3.3.2.2 Expensive extraction processes for cannabinoids
      • 3.3.2.3 Absence of definite regulatory framework for minor cannabinoids
      • 3.3.2.4 Limited research is hindering the growth of the cannabinoids market
  • 3.4 U.S. Cannabinoids Market Analysis Tools
    • 3.4.1 U.S. Cannabinoids Market - PESTLE Analysis
    • 3.4.2 U.S. Cannabinoids Market - PORTER'S Analysis
  • 3.5 COVID Impact Analysis
  • 3.6 Supply Chain Analysis
    • 3.6.1 Supply Chain Analysis - CBD Consumer Health Product
  • 3.7 Product Adoption Pattern Analysis
    • 3.7.1 Cannabidiol (CBD)
    • 3.7.2 Tetrahydrocannabinol (THC)
    • 3.7.3 Cannabinol (CBN)
    • 3.7.4 Cannabidiolic Acid (CBDA)
    • 3.7.5 Others
      • 3.7.5.1 Cannabigerol (CBG)
      • 3.7.5.2 Cannabichromene (CBC)
  • 3.8 Biosynthetic Cannabinoids
  • 3.9 Upcoming Trends in U.S. Minor Cannabinoids Market
    • 3.9.1 Diversification Of Products:
    • 3.9.2 Increased Availability Of Minor Cannabinoids:
    • 3.9.3 More Brands Entering The Market:
    • 3.9.4 Growing Demand For Natural Remedies:
  • 3.10 TAM-SAM-SOM Analysis
  • 3.11 Transcript of an industry KOL
  • 3.12 Key Analysis from the Primary Respondents

Chapter 4 U.S. Cannabinoids Market Segment Analysis, By Product Type, 2018 - 2030 (USD Million)

  • 4.1 Definition and Scope
  • 4.2 Product Type Market Share Analysis, 2022 & 2030
  • 4.3 Segment Dashboard
  • 4.4 U.S. Cannabinoids Market, by Product Type, 2018 to 2030
  • 4.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 4.5.1 Cannabidiol (CBD)
      • 4.5.1.1 Cannabidiol (CBD) market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.2 Tetrahydrocannabinol (THC)
      • 4.5.2.1 Tetrahydrocannabinol (THC) market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.3 Cannabinol (CBN)
      • 4.5.3.1 Cannabinol (CBN) market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.4 Cannabigerolic Acid (CBGA)
      • 4.5.4.1 Cannabigerolic acid (CBGA) market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.5 Cannabigerol (CBG)
      • 4.5.5.1 Cannabigerol (CBG) market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.6 Cannabichromene (CBC)
      • 4.5.6.1 Cannabichromene (CBC) market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.7 Tetrahydrocannabivarin (THCV)
      • 4.5.7.1 Tetrahydrocannabivarin (THCV) market estimates and forecast, 2018 - 2030 (USD Million)
    • 4.5.8 Others
      • 4.5.8.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5 U.S. Cannabinoids Market Segment Analysis, By Application 2018 - 2030 (USD Million)

  • 5.1 Definition and Scope
  • 5.2 Application Market Share Analysis, 2022 & 2030
  • 5.3 Segment Dashboard
  • 5.4 U.S. Cannabinoids Market, by Application, 2018 to 2030
  • 5.5 Market Size & Forecasts and Trend Analyses, 2018 to 2030
    • 5.5.1 Inflammation
      • 5.5.1.1 Inflammation market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.2 Pain Management
      • 5.5.2.1 Pain management market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.3 Neurological Disorders
      • 5.5.3.1 Neurological disorders market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.4 Cancer
      • 5.5.4.1 Cancer market estimates and forecast, 2018 - 2030 (USD Million)
    • 5.5.5 Others
      • 5.5.5.1 Others market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6 U.S. Cannabinoids Market - Competitive Analysis

  • 6.1 Recent Developments & Impact Analysis, by Key Market Participants
    • 6.1.2 Heat map analysis
    • 6.1.3 Major Deals and Strategic Alliances Analysis
      • 6.1.3.1 Joint Ventures
      • 6.1.3.2 Licensing Agreements
      • 6.1.3.3 Product Launches
  • 6.2 Company Categorization
    • 6.2.1 Innovators
    • 6.2.2 Market Leaders
  • 6.3 Company Market Position Analysis
  • 6.4 Company Profiles
    • 6.4.1 Mile High Labs
      • 6.4.1.1 Company overview
      • 6.4.1.2 Financial performance
      • 6.4.1.3 Product benchmarking
      • 6.4.1.4 Strategic Initiatives
    • 6.4.2 Global Cannabinoids
      • 6.4.2.1 Company overview
      • 6.4.2.2 Financial performance
      • 6.4.2.3 Product benchmarking
      • 6.4.2.4 Strategic Initiatives
    • 6.4.3 GenCanna
      • 6.4.3.1 Company overview
      • 6.4.3.2 Financial performance
      • 6.4.3.3 Product benchmarking
      • 6.4.3.4 Strategic Initiatives
    • 6.4.4 CBD Inc.
      • 6.4.4.1 Company overview
      • 6.4.4.2 Financial performance
      • 6.4.4.3 Product benchmarking
      • 6.4.4.4 Strategic Initiatives
    • 6.4.5 Precision Plant Molecules
      • 6.4.5.1 Company overview
      • 6.4.5.2 Financial performance
      • 6.4.5.3 Product benchmarking
      • 6.4.5.4 Strategic Initiatives
    • 6.4.6 Rhizo Sciences
      • 6.4.6.1 Company overview
      • 6.4.6.2 Financial performance
      • 6.4.6.3 Product benchmarking
      • 6.4.6.4 Strategic Initiatives
    • 6.4.7 LaurelCrest
      • 6.4.7.1 Company overview
      • 6.4.7.2 Financial performance
      • 6.4.7.3 Product benchmarking
      • 6.4.7.4 Strategic initiatives
    • 6.4.8 Fresh Bros Hemp Company
      • 6.4.8.1 Company overview
      • 6.4.8.2 Financial performance
      • 6.4.8.3 Product benchmarking
      • 6.4.8.4 Strategic initiatives
    • 6.4.9 BulKanna
      • 6.4.9.1 Company overview
      • 6.4.9.2 Financial performance
      • 6.4.9.3 Product benchmarking
      • 6.4.9.4 Strategic initiatives
    • 6.4.10 High-Purity Natural Products
      • 6.4.10.1 Company overview
      • 6.4.10.2 Financial performance
      • 6.4.10.3 Product benchmarking
      • 6.4.10.4 Strategic initiatives
    • 6.4.11 Zero Point Extraction, LLC
      • 6.4.11.1 Company overview
      • 6.4.11.2 Financial performance
      • 6.4.11.3 Product benchmarking
      • 6.4.11.4 Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Key companies undergoing collaboration
  • Table 4 Key companies undergoing partnership
  • Table 5 Key companies undergoing product launch
  • Table 6 Key companies undergoing new products/services

List of Figures

  • Fig. 1 U.S. cannabinoids market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook (2022)
  • Fig. 10 Strategy framework
  • Fig. 11 Market driver relevance analysis (Current & future impact)
  • Fig. 12 Market restraint relevance analysis (Current & future impact)
  • Fig. 13 Penetration & growth prospect mapping
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 U.S. cannabinoids market: Product type movement analysis
  • Fig. 17 U.S. cannabinoids market: Product type segment dashboard
  • Fig. 18 U.S. cannabinoids market product type outlook: Key takeaways
  • Fig. 19 Tetrahydrocannabinol (THC) U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Cannabidiol (CBD) U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Cannabigerol (CBG) U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Cannabichromene (CBC) U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Cannabinol (CBN) U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Tetrahydrocannabivarin (THCV) U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Cannabigerolic Acid (CBGA) U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Others U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. cannabinoids market: Application movement analysis
  • Fig. 28 U.S. cannabinoids market: Application segment dashboard
  • Fig. 29 U.S. cannabinoids market Application outlook: Key takeaways
  • Fig. 30 Inflammation U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Pain Management U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Neurological Disorders U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Cancer U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Others U.S. cannabinoids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Heat map analysis
  • Fig. 36 Market differentiators